Celtic finalises deal to move Resolvyx' dry eye treatment through Phase III
This article was originally published in Scrip
Celtic Therapeutic Holdings, the global private equity firm, has finalised an exclusive option deal announced in October with Resolvyx Pharmaceuticals to further develop a RX-10045, a late-stage topical eye-drop that has shown potential for treating dry eye syndrome and other ophthalmic conditions. Under the terms of the deal, Celtic has acquired and licensed worldwide rights to RX-10045 in exchange for up-front consideration, near-term milestone payments, and funding for 100% of future development costs (details of all of which were undisclosed).
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.